Meeting
2020 ASCO Virtual Scientific Program
Type of prior genotoxic insult determines the genomic characteristics of therapy-related acute myeloid leukemia.
Authors
Michael Ozga
The Ohio State University Wexner Medical Center, Columbus, OH
Michael Ozga , James Stewart Blachly , Nicole Renee Grieselhuber , Karilyn T.M. Larkin , Alison R. Walker , Bhavana Bhatnagar , Gregory Behbehani , Meixiao Long , Tamanna Zohra Haque , Sumithira Vasu , Weiqiang Zhao , Daniel Jones , John C. Byrd , Alice S. Mims , Caner Saygin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7515)
DOI
10.1200/JCO.2020.38.15_suppl.7515
Abstract #
7515
Poster Bd #
288
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.
First Author: Maha AT Elsebaie
Poster
2023 ASCO Annual Meeting
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
First Author: Jeffrey Lee Jensen
Poster
2023 ASCO Annual Meeting
Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.
First Author: Justin M. Watts
Poster
2018 ASCO Annual Meeting
Molecular testing during AML treatment for early prediction of clinical response.
First Author: Hong Yuen Wong